{
    "clinical_study": {
        "@rank": "112742", 
        "arm_group": {
            "arm_group_label": "Semaglutide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the absorption,\n      metabolism and excretion after a single subcutaneous dose of [3H]-semaglutide in healthy\n      male subjects."
        }, 
        "brief_title": "Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects, based on an assessment of medical history, physical\n             examination, ECG (electrocardiogram) and vital signs, as determined by the\n             investigator\n\n          -  Age between 45-64 years (both inclusive) at the time of signing inform consent\n\n          -  Body mass index (BMI) between 20 and 30 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Donation of any blood or plasma in the past month or in excess of 100 mL within the 3\n             months preceding screening, or surgery or trauma with more than 100 mL blood loss\n             within the 3 months preceding screening\n\n          -  Use of prescription or non-prescription systemic or topical medicinal products\n             (except routine vitamins, acetylsalicylic acid and paracetamol) within 3 weeks (or\n             within 5 half-lives of the medicinal product, whichever is longest) prior to visit 2,\n             Day 1\n\n          -  History of drug/chemical substance abuse within 1 year from screening, or a positive\n             result in the urine drug test\n\n          -  History of alcohol abuse within 1 year from screening, or a positive result in the\n             alcohol urine test, or consumption of more than 21 units of alcohol weekly (one unit\n             of alcohol equals about 250 mL of beer or lager, one glass (120 mL) of wine, or 20 mL\n             spirits)\n\n          -  Smoking or use of any nicotine (including nicotine patches, gum, etc) in the last 3\n             months prior to screening or a positive nicotine test"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060266", 
            "org_study_id": "NN9535-3789", 
            "secondary_id": [
                "2013-001769-18", 
                "U1111-1142-0810"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Semaglutide", 
            "description": "Subjects will receive a single dose subcutaneously (s.c., under the skin).", 
            "intervention_name": "semaglutide", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands", 
                    "zip": "9471 GP"
                }
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: Dutch Health Care Inspectorate", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Concentration of the major metabolites of [3H]\u2212semaglutide in plasma, urine, and faeces", 
            "safety_issue": "No", 
            "time_frame": "Up to 9 weeks following a single dose of 0.5 mg [3H]\u2212semaglutide"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060266"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total amount of [3H]\u2212semaglutide related material excreted in urine (% of dose)", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks following a single dose of 0.5 mg [3H]\u2212semaglutide"
            }, 
            {
                "measure": "Total amount of [3H]\u2212semaglutide related material excreted in faeces (% of dose)", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks following a single dose of 0.5 mg [3H]\u2212semaglutide"
            }, 
            {
                "measure": "Blood to plasma ratio of [3H]\u2212semaglutide related material", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks following a single dose of 0.5 mg [3H]\u2212semaglutide"
            }, 
            {
                "measure": "Area under the semaglutide plasma concentration curve", 
                "safety_issue": "No", 
                "time_frame": "From time 0 until infinity after a single dose"
            }, 
            {
                "measure": "Maximum observed semaglutide plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "After a single dose"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}